Sting agonist compounds

US10793557B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael D. Altman · Cambridge, US
• Brandon D. Cash · Framingham, US
• Matthew L. Childers · Medfield, US
• Jared N. Cumming · Garwood, US
• Duane DeMong · Somerville, US
• Andrew M. Haidle · Cambridge, US
• Timothy J. Henderson · Natick, US
• James P. Jewell · Jersey City, US
• Matthew A. Larsen · Dedham, US
• Jongwon Lim · Lexington, US
• Min Lu · San Diego, US
• Ryan D. Otte · Natick, US
• Benjamin Wesley Trotter · Medfield, US

Key dates

• Filing date: Apr 1, 2019
• Grant date: Oct 6, 2020
• Expiry date: Apr 1, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.